Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis

Journal of Cellular Biochemistry

Volumn 113, Issue 2, 2012, Pages 457-464

  Park, Jounghyen ^a   Park, Ok Jin ^a   Yoon, Won Joon ^a   Kim, Hyun Jung ^a   Choi, Kang Young ^a   Cho, Tae Joon ^a   Ryoo, Hyun Mo ^a  

^a Seoul National University   (South Korea)

Author keywords

Apert syndrome; Craniosynostosis; ERK pathway; FGFR2; Phosphorylation; Runx2

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

3T3 CELLS; ACROCEPHALOSYNDACTYLIA; AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; CELL LINE; CELL PROLIFERATION; CONSERVED SEQUENCE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CRANIOFACIAL DYSOSTOSIS; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHOSPHORYLATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TRANSCRIPTION, GENETIC;

EID: 84862908639     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23368     Document Type: Article

References (43)

1. Ahmed Z, Schuller AC, Suhling K, Tregidgo C, Ladbury JE. 2008. Extracellular point mutations in FGFR2 elicit unexpected changes in intracellular signalling. Biochem J 413:37-49. (Pubitemid 351946860)
2. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7:1475-1483. (Pubitemid 28429929)
3. Baroni T, Carinci P, Lilli C, Bellucci C, Aisa MC, Scapoli L, Volinia S, Carinci F, Pezzetti F, Calvitti M, Farina A, Conte C, Bodo M. 2005a. P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation. J Cell Physiol 202:524-535. (Pubitemid 40041324)
4. Baroni T, Carinci P, Lilli C, Bellucci C, Aisa MC, Scapoli L, Volinia S, Carinci F, Pezzetti F, Calvitti M, et al. 2005b. P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation. J Cell Physiol 202:524-535. (Pubitemid 40041324)
5. Bellus GA, Gaudenz K, Zackai EH, Clarke LA, Szabo J, Francomano CA, Muenke M. 1996. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet 14:174-176. (Pubitemid 26338798)
6. Chaudhary LR, Avioli LV. 1997. Activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) by FGF-2 and PDGF-BB in normal human osteoblastic and bone marrow stromal cells: Differences in mobility and ingel renaturation of ERK1 in human, rat, and mouse osteoblastic cells. Biochem Biophys Res Commun 238:134-139. (Pubitemid 27453288)
7. Cohen MM, Jr, Kreiborg S. 1993. Growth pattern in the Apert syndrome.Am J Med Genet 47:617-623. (Pubitemid 23291973)
8. Debiais F, Lemonnier J, Hay E, Delannoy P, Caverzasio J, Marie PJ. 2001. Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. J Cell Biochem 81:68-81.
9. Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P. 2004. A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA 101:12555-12560. (Pubitemid 39122062)
10. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149. (Pubitemid 40616112)
11. Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz deLuna RI, Garcia Delgado C, Gonzalez-Ramos M, Kline AD, Jabs EW. 1997. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 15:36-41. (Pubitemid 27014947)
12. Jabs EW, Li X, Scott AF, Meyers G, Chen W, Eccles M, Mao JI, Charnas LR, Jackson CE, Jaye M. 1994. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet 8:275-279. (Pubitemid 24338740)
13. Kan SH, Elanko N, Johnson D, Cornejo-Roldan L, Cook J, Reich EW, Tomkins S, Verloes A, Twigg SR, Rannan-Eliya S, et al. 2002. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet 70:472-486. (Pubitemid 34112300)
14. Kim HJ, Kim JH, Bae SC, Choi JY, Ryoo HM. 2003a. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 278:319-326.
15. Kim HJ, Lee MH, Park HS, Park MH, Lee SW, Kim SY, Choi JY, Shin HI, Kim HJ, Ryoo HM. 2003b. Erk pathway and activator protein 1 play crucial roles in FGF2-stimulated premature cranial suture closure. Dev Dyn 227:335-346.
16. Kim HJ, Lee MH, Park HS, Park MH, Lee SW, Kim SY, Choi JY, Shin HI, Ryoo HM. 2003c. Erk pathway and activator protein 1 play crucial roles in FGF2-stimulated premature cranial suture closure. Dev Dyn 227:335-346.
17. Kim HJ, Park HD, Kim JH, Cho JY, Choi JY, Kim JK, Shin HI, Ryoo HM. 2004. Establishment and characterization of a stable cell line to evaluate cellular Runx2 activity. J Cell Biochem 91:1239-1247.
18. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764. (Pubitemid 27516178)
19. Kuo WL, Chung KC, Rosner MR. 1997. Differentiation of central nervous system neuronal cells by fibroblast-derived growth factor requires at least two signaling pathways: Roles for Ras and Src. Mol Cell Biol 17:4633-4643. (Pubitemid 27318139)
20. Larsson H, Klint P, Landgren E, Claesson-Welsh L. 1999. Fibroblast growth factor receptor-1-mediated endothelial cell proliferation is dependent on the Src homology (SH) 2/SH3 domain-containing adaptor protein Crk. J Biol Chem 274:25726-25734.
21. Lemonnier J, Hay E, Delannoy P, Fromigue O, Lomri A, Modrowski D, Marie PJ. 2001. Increased osteoblast apoptosis in apert craniosynostosis-Role of protein kinase c and interleukin-1. Am J Pathol 158:1833-1842. (Pubitemid 32422948)
22. Maher P. 1999. p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation. J Biol Chem 274:17491-17498.
23. Meyers GA, Day D, Goldberg R, Daentl DL, Przylepa KA, Abrams LJ, Graham JM, Jr., Feingold M, Moeschler JB, Rawnsley E, et al. 1996. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: Evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 58:491-498.
24. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. 2008. Fibroblast growth factor receptor2 promotes osteogenic differentiation in mesenchymal cells via extracellular-related kinase and protein kinase c signalling. J Biol Chem 284:4879-4904.
25. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J.1996. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 16:977-989. (Pubitemid 26061669)
26. Ornitz DM. 2005. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16:205-213. (Pubitemid 40616117)
27. Ornitz DM, Marie PJ. 2002. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16:1446-1465. (Pubitemid 34686327)
28. Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol 2: reviews3005.1-reviews3005.12.
29. Park OJ, Kim HJ, Woo KM, Baek JH, Ryoo HM. 2010. FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization. J Biol Chem 285:3568-3574.
30. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. 2000. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101:413-424.
31. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S. 1994. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8:98-103. (Pubitemid 24274068)
32. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Thesleff I. 2000. Integration of FGF and TWIST in calvarial bone and suture development. Development 127:1845-1855. (Pubitemid 30311788)
33. Rutland P, Pulleyn LJ, Reardon W, Baraitser M, Hayward R, Jones B, Malcolm S, Winter RM, Oldridge M, Slaney SF, et al. 1995. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet 9:173-176.
34. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
35. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. 1994. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 79:1015-1024.
36. Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H, Matsumoto T, Marie PJ, Moriyama K. 2004. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 279:45926-45934. (Pubitemid 39491585)
37. Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, Cai J, Lerner CP, Richtsmeier JT, Leszl JM, Hill CA, et al. 2005. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development 132:3537-3548. (Pubitemid 41246127)
38. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, et al. 2005. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361-367. (Pubitemid 40129563)
39. Wilkie AO. 1997. Craniosynostosis: Genes and mechanisms. Hum Mol Genet 6:1647-1656. (Pubitemid 27401607)
40. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P, et al. 1995. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9:165-172.
41. Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J, et al. 2008. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42:631-643.
42. Zhang Y, Gorry MC, Post JC, Ehrlich GD. 1999. Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family. Gene 230:69-79. (Pubitemid 29193197)
43. Zellin G, Linde A. 2000. Effects of recombinant human fibroblast growth factor-2 on osteogenic cell populations during orthopic osteogenesis in vivo. Bone 26:161-168. (Pubitemid 30029209)